Sentinel lymph node mapping for carcinoma of the colon: a pilot study

Area of Science:

• Surgical Oncology
• Gastrointestinal Cancer Research
• Diagnostic Pathology

Background:

• Sentinel lymph node (SLN) mapping is standard for melanoma and breast cancer, but under-evaluated in colon cancer.
• Accurate staging of colon cancer relies on regional lymph node assessment.

Purpose of the Study:

• To evaluate the feasibility, safety, and accuracy of SLN mapping in patients with colon cancer.
• To assess the utility of immunohistochemistry (Imm) in conjunction with SLN mapping for improved staging.

Main Methods:

• SLN mapping using isosulfan blue dye in 22 patients with adenocarcinoma of the colon.
• Visual identification and excision of SLNs, followed by standard lymphadenectomy.
• Analysis of SLNs via hematoxylin and eosin (H&E) and immunohistochemistry (Imm) for carcinoembryonic antigen and cytokeratin.

Main Results:

• SLN mapping was successful in 20 of 22 patients, adding minimal operative time (approx. 5 minutes) with no adverse reactions.
• SLNs accurately predicted the status of all regional nodes in cases with negative or positive findings (100% concordance).
• Immunohistochemistry identified metastatic disease in one SLN not detected by H&E, leading to patient upstaging.

Conclusions:

• Sentinel lymph node mapping is a feasible and safe procedure for colon cancer patients.
• Combined SLN mapping and Imm techniques can improve staging accuracy and identify at-risk patients.
• Further large-scale prospective trials are warranted to validate SLN mapping for colon cancer management.